Arcturus Therapeutics to Attend Upcoming Investor Conferences

SAN DIEGO--(BUSINESS WIRE)-- Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”, Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines company focused on the development of infectious disease vaccines and opportunities within liver and respiratory rare diseases, today announced that the Company will participate in the following investor conferences:

Citi’s 18th Annual BioPharma Conference 2023 (Hosting 1x1 meetings)

• Wednesday, September 6 – 7, 2023

2023 Wells Fargo Health Conference (Fireside Chat)

• Thursday, September 7, 2023 (1:30 p.m. ET)

H.C. Wainwright 25th Annual Global Investment Conference 2023 (Presentation)

• Monday, September 11, 2023 (8:30 a.m. ET)

Baird Global Healthcare Conference 2023 (Presentation)

• Tuesday, September 12, 2023 (3:10 p.m. ET)

2023 Cantor Fitzgerald Global Healthcare Conference (Fireside Chat)

• Tuesday - Thursday, September 26 – 28, 2023

Chardan’s 7th Annual Genetic Medicines Conference 2023 (Hosting 1X1 meetings)

• Monday - Tuesday, October 2 – 3, 2023

Webcast links can be found under Investor Relations/Events section of Arcturus’ website.

About Arcturus Therapeutics

Founded in 2013 and based in San Diego, California, Arcturus Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage clinical mRNA medicines and vaccines company with enabling technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA Technology (samRNA) and (iii) mRNA drug substance along with drug product manufacturing expertise. The Company has ongoing collaborations with CSL Seqirus and Meiji Seika Pharma, and a joint venture with ARCALIS. Arcturus’ pipeline includes RNA therapeutic candidates to potentially treat ornithine transcarbamylase deficiency and cystic fibrosis, along with its partnered mRNA vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’ versatile RNA therapeutics platforms can be applied toward multiple types of nucleic acid medicines including messenger RNA, small interfering RNA, circular RNA, antisense RNA, self-amplifying RNA, DNA, and gene editing therapeutics. Arcturus’ technologies are covered by its extensive patent portfolio (patents and patent applications issued in the U.S., Europe, Japan, China, and other countries). For more information, visit www.ArcturusRx.com. In addition, please connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230817580897/en/

IR and Media Contacts
Arcturus Therapeutics
Neda Safarzadeh
VP, Head of IR/PR/Marketing
(858) 900-2682
[email protected]

Kendall Investor Relations
Carlo Tanzi, Ph.D.
(617) 914-0008
[email protected]

Source: Arcturus Therapeutics

You May Also Be Interested In

• E3 Lithium Releases Q2 2026 Results and Advances Key Strategic Milestones
• Legend Power Systems Schedules Q3 2026 Financial Results Release and Webinar for August 28, 2026
• Canadian Banking Regulator Urged to Rethink Climate Risk Guideline says Friends of Science; Keystone XL could REcarbonize Canada